Back To Search Results

Ataxia Telangiectasia

Editor: Steven Frucht Updated: 7/3/2023 11:15:26 PM


Ataxia telangiectasia (A-T), also known as Louis-Bar syndrome, is a rare genetic form of early-onset autosomal recessive ataxia. The clinical picture is characterized by a combination of neurological and systemic symptoms due to the mutation of the ataxia telangiectasia mutated (ATM) gene. In particular, the disease is characterized by cerebellar atrophy with progressive ataxia, cutaneous telangiectasias, a higher incidence of malignancy (particularly lymphoid malignancy), radiosensitivity, immune deficiency, recurrent sinopulmonary infections, and high levels of alpha-fetoprotein in serum.


Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care


Ataxia telangiectasia is due to mutations of the ATM gene, located on chromosome 11q22-23.[1] A mutation of the ATM gene is responsible for aberrant repairing of the breaks of double-strand DNA. Because of this defect, cell response to different pathogenic triggers, such as ionizing radiation and alkylating agents, is impaired. As a consequence, cell death occurs in susceptible tissues such as the cerebellum, and malignant proliferation arises.


The incidence of A-T ranges from 1:40,000 to 1:100,000. In some populations, the disease is as rare as 1:300,000.[2] In the United States, about 1% of the population is a carrier of a mutation in the ATM gene.[3] Males and females are equally affected by A-T. Ataxia telangiectasia is the second most common autosomal recessive ataxia in children, after Friedreich’s ataxia, but it is the most common genetic ataxia with onset in the first decade. A significant founder effect has been reported among different populations, especially among the North African Jewish community.


Mutations of the ATM gene are responsible for A-T. Nonsense, frameshift, missense, and insertion-deletion mutations of the ATM gene associated with A-T have been described. In the majority of cases, mutations lead to a truncated and thus nonfunctional protein. Compound heterozygous mutations are not infrequent as well.

ATM is involved in many different molecular mechanisms.[4] The protein is most important for cellular DNA repair, cell cycle control, and cellular response to external triggers, such as oxidative damage, ionizing radiation, and alkylating agents. The protein itself is a serine/threonine kinase affecting many different downstream targets that are involved in those pathways important for cellular protection against toxic insults. The loss of function of the ATM protein is therefore responsible for the aberrant proliferation of cells due to the unrepaired double-strand DNA breaks, increasing the cancer risk and the radiosensitivity. Also, the impairment of cell cycle control can cause malformations, such as gonadal dysgenesis, which is found in patients with A-T. Moreover, ATM is important also for immunoglobulin production and lymphoid cell survival. This explains why ATM mutations are responsible for a higher risk of tumors of the lymphatic system and autoimmune manifestations.

The mechanism underlying the formations of telangiectasia remains unknown. This condition results in dilated blood vessels and is one of the hallmarks of the disorder.


Autopsy cases of A-T mainly reported cerebellar cortex degeneration. Purkinje cells and granular cells are especially affected. As the disease progress, gradual degeneration of other parts of the brain, specifically the brainstem, posterior and anterior horns of the spinal cord occurs.[5]

History and Physical

The classical form of A-T presents early during the first decade. Usually, ataxia is the first noticeable sign. In particular, it can be noticed as instability of the trunk when toddlers are sitting or as an unstable gait. Because of the ataxia, patients often need a wheelchair-accessible vehicle by the age of 10. As the disease progresses, dysarthria and oculomotor apraxia manifest, sometimes affecting vision and reading skills that can impact children during their first years of school. Nystagmus, saccadic intrusions, and hypometric saccades can be present as well. 

Telangiectasias, which are the other distinctive feature of the disease, are present in almost all cases. They usually become evident after the age of 6. Telangiectasias occur most frequently in the eyes, in particular in the conjunctiva, and/or in sun-exposed areas (such as the face and ears).[6] They can also be found in the brain and the bladder.[7] Telangiectasias do not evolve and do not tend to bleed. Other skin manifestations previously reported in these patients are premature aging and cutaneous graying.

Not infrequently, other neurological manifestations can be present. In particular, basal ganglia involvement is common, manifesting with tremor, parkinsonism, chorea, dystonia, and myoclonus. Axonal neuropathy is part of the clinical picture of A-T as well.[8] The latter may be responsible for the orthopedic abnormalities frequently observed in these patients. Mild to moderate cognitive impairment have been reported and can affect different domains, such as language, memory, and executive functions. However, these symptoms can be variably present and show a wide spectrum in the degree of severity.[9]

Immunological impairment is common, affecting about two-thirds of cases. Usually, patients present with low IgA and IgG levels, with variable IgM, which can be either low or high, together with low total CD4 cell count.[10] The immunodeficiency predisposes to recurrent infections, in particular, sinopulmonary infections, as well as to autoimmune and chronic inflammatory diseases. However, autoimmune deficiency is not progressive over time. The combination of recurrent pulmonary infections and restrictive pulmonary disease which are common in these patients can end up in bronchiectasis and interstitial lung diseases.[11]

About 25% to 30% of patients with A-T will develop a tumor. Most frequently leukemia and lymphoma arise early in life. Later on, solid tumors such as breast and ovarian cancer, melanomas, gastric, or liver tumors can present.[12] Tumors can also be associated with severe radiosensitivity. In particular, x-ray and gamma-ray but not ultraviolet (UV) have been reported to be detrimental in patients with A-T, and therefore, should be avoided.

Insulin resistance or diabetes, as well as hypercholesterolemia and steatosis, can be present, especially later in the course of the disease. The endocrine system can also be involved in growth hormone deficiency, resulting in short stature and failure to grow, and gonadal failure, causing infertility.[13] Both of these symptoms are more frequent in females. Microcephaly has been reported as well.

Variant Forms

Some authors reported an adult-onset form of A-T which is characterized by a much milder phenotype that manifests later in life and progresses slowly. An intermediate phenotype that still presents during the first or second decade but is milder in course has also been reported.[14]

Ataxia-Telangiectasia-Like Phenotypes

Different genetic mutations have been found in patients with a phenotypic presentation similar to A-T.[15]

In particular, mutations of the genes NBS1 (nibrin) or MRE11, which encode for 2 proteins whose functions are strictly related to ATM, have been associated with diseases that resemble A-T. Nijmegen breakage syndrome, which is caused by the mutation of the NBS1 gene, is characterized by an increased risk of cancer, microcephaly, and syndromic features, recurrent respiratory infections, and intellectual disability. Ataxia and telangiectasia are not present.

Ataxia-telangiectasia-like disorder 1 (ATLD1), instead, is caused by the genetic mutations of the MRE11 gene. This disorder can present with progressive ataxia, oculomotor apraxia, and dysarthria, but without telangiectasias. Moreover, the age of onset can be delayed compared to A-T, and the level of immunoglobulin in the peripheral blood is usually normal.


The diagnosis of A-T can be challenging due to the rarity of the disorder. The diagnosis is usually based on the following features:

Clinical Picture

Early-onset of ataxia within the first decade in the classical form and oculomotor apraxia are usually crucial to narrow the diagnostic algorithm. The concomitant presence of tumors may raise the suspicion of A-T. The cohort of other symptoms, such as other neurological manifestations, the involvement of the immunological, pulmonary, and endocrinological systems, can help in the diagnosis as well. 


Telangiectasias are present in almost all patients, and therefore, are an important and almost unequivocal sign to make the correct diagnosis. However, telangiectasias are not always easy to recognize. Moreover, they can present in unusual locations, and therefore, can go undetected if not searched for attentively.


Cerebellar atrophy mostly involving the vermis is the cardinal radiological feature of this disease. Brain magnetic resonance imaging (MRI) is the best current imaging for these findings. Cerebellar atrophy becomes more prominent with age and may be absent early on. In older patients, white matter abnormalities have been reported as well.

Laboratory Tests

Elevation of the alpha-fetoprotein is a characteristic feature of A-T, even if it is not exclusive of this condition. Blood tests can also show a decrease in the total amount of IgG and IgA and variable levels of IgM.

Genetic Testing

The definitive diagnosis of A-T is reached through the detection of homozygous or compound heterozygous mutation of the ATM gene that can be reached through targeted sequencing of the gene, or through sequencing done as part of ataxia panels or whole-exome sequencing. In the case of a new gene variant, immunoblotting of the ATM protein can be performed to confirm whether the detected mutation causes a significant reduction of the levels of ATM.

Treatment / Management

The management of patients with A-T requires an interprofessional team since the disease presents with a great variety of manifestations.[16] A specific treatment to cure this disease is not available yet. Therefore, addressing the specific symptoms associated with the disease and surveillance to prevent complications is crucial

Neurological  Symptoms

Ataxia and other neurological manifestation can severely affect patients’ everyday life. Physical therapy and regular assessment for possible aids that may be needed are extremely important. One of the main goals of these assessments should be to prevent complications such as falls. Children usually require support at school because of the motor and cognitive impairment.

Cancer and Radiosensitivity 

Proper surveillance for breast and ovary cancer can be lifesaving. Hematological tumors cannot be prevented, but regular monitoring can allow early diagnosis. The treatment of these tumors is not different from the best standard of care approach; specific care must be considered due to the radiosensitivity of these patients.

Immunological Disease

Treatment of recurrent infections and prophylactic antibiotic administration, when required, have been able to prolong life expectancy in patients with A-T. Intravenous immunoglobulin has been considered a good option for these patients as well. While inactivated vaccinations have not been associated with complications in patients with A-T, live vaccines may be contraindicated, especially in the presence of a low T-cell count.

Complications secondary to restrictive lung disease must always be considered in case of anesthesia or surgery.[17] Pulmonary complications can be prevented with adequate surveillance of pulmonary function and prevention of recurrent respiratory infections.(B2)

Future Treatments 

Antioxidant, antisense morpholino oligonucleotides (AMO), aminoglycoside antibiotics that can affect ATM protein function, as well as different small molecules targeting the ATM gene to address tumorigenesis, have been tested. Most of these new therapeutic approaches are still under investigation.[18] Therapeutic trials are ongoing to test the efficacy of treatment with dexamethasone through innovative ways of delivery such as patients’ autologous red blood cells loaded with dexamethasone (ATTeST study).(B3)

Differential Diagnosis

The main categories of diseases that must be considered in the differential diagnosis of A-T are as follows:

Recessive Forms of Ataxia

These disorders usually present at an early age, and no other family members are affected. Autosomal recessive disorders are more common in cases of consanguinity in the family. The list of autosomal recessive ataxia is very long, and the incidence of these disorders can vary in different populations. Among autosomal recessive ataxia, Friedreich’s ataxia can be easily misdiagnosed as A-T since both can present with early-onset cerebellar ataxia, polyneuropathy, and systemic involvement. The other autosomal recessive cerebellar ataxias can be grouped into metabolic disorders (such as abetalipoproteinemia, cerebrotendinous xanthomatosis, Refsum disease), congenital ataxias like Joubert syndrome, degenerative disease such as Charlevoix-Saguenay spastic ataxia, mitochondrial disorders like myoclonic epilepsy with ragged-red fibers (MERRF), NARP syndrome (neuropathy, ataxia, retinitis pigmentosa), sensory ataxic neuropathy with dysarthria and ophthalmoplegia (SANDO), infantile-onset spinocerebellar ataxia (IOSCA), and Marinesco-Sjogren syndrome.[19]

Ataxia with Oculomotor Apraxia

Oculomotor apraxia is a distinctive sign of A-T. However, there are other disorders where this can be found. Ataxia with oculomotor apraxia types 1 and 2 (AOA1 and AOA2) are autosomal recessive ataxias characterized by an early age of onset. The systemic symptoms which are commonly found in patients with A-T are not characteristically seen in these other forms.[20]

Ataxia-Telangiectasia-Like Disorders (ATLD)

The disorders due to the mutations of the MRE11 gene and the NBS1 genes, associated with the ATDL1 and the Nijmegen breakage syndrome (NBS), should always be considered when assessing the diagnosis of an early onset progressive ataxia and/or the concomitant presence of immunological deficit, tumorigenesis and growth failure. However, both of these disorders lack the typical telangiectasias.[15]


In these patients, the overall survival is greatly affected by attentive care and careful screening, which allow the prevention of recurrent infections and identifying tumors early. Usually, patients affected by the classical form of A-T can reach early adulthood. Milder forms and adult-onset variants have a significantly longer life expectancy. Median survival was noted to be 19-25 years with wide variability in two large cohorts.[21] The atypical forms of the disease usually present with a milder phenotype and a much longer life expectancy.[21]


  • Cognitive impairment
  • Neurologic deficits
  • Increased fall risk
  • Pulmonary disease
  • Recurrent infections
  • Malignancy

Deterrence and Patient Education

Parents and patients with A-T should be educated regarding the importance of monitoring for malignancy and the prevention of recurrent infection. If antibiotics are prescribed, medication adherence and the consequences of inadequate treatment should be explained in depth. Due to the severe radiosensitivity of these patients, x-ray and gamma-ray exposure should be avoided.

Pearls and Other Issues

Carriers of the ATM gene mutation have an increased risk of cancer and, as a result, reduced life expectancy. The incidence of radiosensitivity in carriers is still debated.

Enhancing Healthcare Team Outcomes

Since the disease presents with a great variety of manifestations, the management of patients with A-T requires an interprofessional team that includes a geneticist, pediatrician, neurologist, oncologist, dermatologist, nurse practitioner, and an infectious disease expert.[16] A specific treatment to cure this disease is not available yet. Therefore, addressing the specific symptoms associated with the disease and surveillance to prevent complications is crucial.

In these patients, the overall survival is greatly affected by the attentive care and careful screening, which allow prevention of recurrent infections and identifying tumors early. Usually, patients affected by the classical form of A-T can reach early adulthood. Milder forms and adult-onset variants have a significantly longer life expectancy. The atypical forms of the disease usually present with a milder phenotype and a much longer life expectancy.[21]


(Click Image to Enlarge)
This photo shows the prominent ocular telangiectasia that can be seen in some people with A-T.
This photo shows the prominent ocular telangiectasia that can be seen in some people with A-T.
Contributed by Wikimedia Commons, Thomas O. Crawford (Public Domain)



Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, Ashkenazi M, Pecker I, Frydman M, Harnik R, Patanjali SR, Simmons A, Clines GA, Sartiel A, Gatti RA, Chessa L, Sanal O, Lavin MF, Jaspers NG, Taylor AM, Arlett CF, Miki T, Weissman SM, Lovett M, Collins FS, Shiloh Y. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science (New York, N.Y.). 1995 Jun 23:268(5218):1749-53     [PubMed PMID: 7792600]


Gilad S, Bar-Shira A, Harnik R, Shkedy D, Ziv Y, Khosravi R, Brown K, Vanagaite L, Xu G, Frydman M, Lavin MF, Hill D, Tagle DA, Shiloh Y. Ataxia-telangiectasia: founder effect among north African Jews. Human molecular genetics. 1996 Dec:5(12):2033-7     [PubMed PMID: 8968760]


Swift M, Morrell D, Cromartie E, Chamberlin AR, Skolnick MH, Bishop DT. The incidence and gene frequency of ataxia-telangiectasia in the United States. American journal of human genetics. 1986 Nov:39(5):573-83     [PubMed PMID: 3788973]


Zaki-Dizaji M, Akrami SM, Abolhassani H, Rezaei N, Aghamohammadi A. Ataxia telangiectasia syndrome: moonlighting ATM. Expert review of clinical immunology. 2017 Dec:13(12):1155-1172. doi: 10.1080/1744666X.2017.1392856. Epub 2017 Oct 20     [PubMed PMID: 29034753]


Verhagen MM, Martin JJ, van Deuren M, Ceuterick-de Groote C, Weemaes CM, Kremer BH, Taylor MA, Willemsen MA, Lammens M. Neuropathology in classical and variant ataxia-telangiectasia. Neuropathology : official journal of the Japanese Society of Neuropathology. 2012 Jun:32(3):234-44. doi: 10.1111/j.1440-1789.2011.01263.x. Epub 2011 Oct 24     [PubMed PMID: 22017321]

Level 3 (low-level) evidence


Greenberger S, Berkun Y, Ben-Zeev B, Levi YB, Barziliai A, Nissenkorn A. Dermatologic manifestations of ataxia-telangiectasia syndrome. Journal of the American Academy of Dermatology. 2013 Jun:68(6):932-6. doi: 10.1016/j.jaad.2012.12.950. Epub 2013 Jan 27     [PubMed PMID: 23360865]

Level 2 (mid-level) evidence


Lin DD, Barker PB, Lederman HM, Crawford TO. Cerebral abnormalities in adults with ataxia-telangiectasia. AJNR. American journal of neuroradiology. 2014 Jan:35(1):119-23. doi: 10.3174/ajnr.A3646. Epub 2013 Jul 25     [PubMed PMID: 23886747]


Nissenkorn A, Levi YB, Vilozni D, Berkun Y, Efrati O, Frydman M, Yahav J, Waldman D, Somech R, Shenhod E, Menascu S, Ben-Zeev B. Neurologic presentation in children with ataxia-telangiectasia: is small head circumference a hallmark of the disease? The Journal of pediatrics. 2011 Sep:159(3):466-471.e1. doi: 10.1016/j.jpeds.2011.02.005. Epub 2011 Mar 22     [PubMed PMID: 21429505]

Level 2 (mid-level) evidence


Woods CG, Taylor AM. Ataxia telangiectasia in the British Isles: the clinical and laboratory features of 70 affected individuals. The Quarterly journal of medicine. 1992 Feb:82(298):169-79     [PubMed PMID: 1377828]


Nowak J, Horst A. Immunologic heterogeneity of the lymphocyte surface in various diseases. Annals of the Medical Section of the Polish Academy of Sciences. 1975:20(3):173-84     [PubMed PMID: 1103513]


McGrath-Morrow SA, Lederman HM, Aherrera AD, Lefton-Greif MA, Crawford TO, Ryan T, Wright J, Collaco JM. Pulmonary function in children and young adults with ataxia telangiectasia. Pediatric pulmonology. 2014 Jan:49(1):84-90. doi: 10.1002/ppul.22760. Epub 2013 Feb 8     [PubMed PMID: 23401357]

Level 2 (mid-level) evidence


Olsen JH, Hahnemann JM, Børresen-Dale AL, Brøndum-Nielsen K, Hammarström L, Kleinerman R, Kääriäinen H, Lönnqvist T, Sankila R, Seersholm N, Tretli S, Yuen J, Boice JD Jr, Tucker M. Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries. Journal of the National Cancer Institute. 2001 Jan 17:93(2):121-7     [PubMed PMID: 11208881]


Nissenkorn A, Levy-Shraga Y, Banet-Levi Y, Lahad A, Sarouk I, Modan-Moses D. Endocrine abnormalities in ataxia telangiectasia: findings from a national cohort. Pediatric research. 2016 Jun:79(6):889-94. doi: 10.1038/pr.2016.19. Epub 2016 Feb 18     [PubMed PMID: 26891003]


Lohmann E, Krüger S, Hauser AK, Hanagasi H, Guven G, Erginel-Unaltuna N, Biskup S, Gasser T. Clinical variability in ataxia-telangiectasia. Journal of neurology. 2015 Jul:262(7):1724-7. doi: 10.1007/s00415-015-7762-z. Epub 2015 May 10     [PubMed PMID: 25957637]


Taylor AM, Groom A, Byrd PJ. Ataxia-telangiectasia-like disorder (ATLD)-its clinical presentation and molecular basis. DNA repair. 2004 Aug-Sep:3(8-9):1219-25     [PubMed PMID: 15279810]


van Os NJH, Haaxma CA, van der Flier M, Merkus PJFM, van Deuren M, de Groot IJM, Loeffen J, van de Warrenburg BPC, Willemsen MAAP, A-T Study Group. Ataxia-telangiectasia: recommendations for multidisciplinary treatment. Developmental medicine and child neurology. 2017 Jul:59(7):680-689. doi: 10.1111/dmcn.13424. Epub 2017 Mar 20     [PubMed PMID: 28318010]


Lockman JL, Iskander AJ, Bembea M, Crawford TO, Lederman HM, McGrath-Morrow S, Easley RB. Anesthetic and perioperative risk in the patient with Ataxia-Telangiectasia. Paediatric anaesthesia. 2012 Mar:22(3):256-62. doi: 10.1111/j.1460-9592.2011.03739.x. Epub 2011 Nov 21     [PubMed PMID: 22098343]

Level 2 (mid-level) evidence


Vecchio D, Frosina G. Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy. Current drug targets. 2016:17(2):139-53     [PubMed PMID: 25382204]

Level 3 (low-level) evidence


Palau F, Espinós C. Autosomal recessive cerebellar ataxias. Orphanet journal of rare diseases. 2006 Nov 17:1():47     [PubMed PMID: 17112370]


Le Ber I, Dürr A, Brice A. Autosomal recessive cerebellar ataxias with oculomotor apraxia. Handbook of clinical neurology. 2012:103():333-41. doi: 10.1016/B978-0-444-51892-7.00020-6. Epub     [PubMed PMID: 21827898]


Crawford TO, Skolasky RL, Fernandez R, Rosquist KJ, Lederman HM. Survival probability in ataxia telangiectasia. Archives of disease in childhood. 2006 Jul:91(7):610-1     [PubMed PMID: 16790721]

Level 2 (mid-level) evidence


Sirajwala AA, Khan S, Rathod VM, Gevariya VC, Jansari JR, Patel YM. Ataxia-Telangiectasia: A Case Report and a Brief Review. Cureus. 2023 May:15(5):e39346. doi: 10.7759/cureus.39346. Epub 2023 May 22     [PubMed PMID: 37351254]

Level 3 (low-level) evidence